Labiana Health

Labiana Health Acquisitions (Net)

The Acquisitions (Net) of Labiana Health (LAB.MC) as of Oct 30, 2026 is -938,300.00 EUR. In the previous year, Acquisitions (Net) was 816,900.00 EUR — a change of -214.86% (lower).

Acquisitions (Net)

-938,300.00EUR

YoY

-214.86%

Last updated:

Acquisitions (Net) of Labiana Health is 2024 -938,300.00 EUR. Acquisitions (Net) of Labiana Health was 2023 816,900.00 EUR. It decreases by -214.86% lower compared to the previous year.

The Labiana Health Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2018
-36,500.00 EUR
Jan 1, 2019
-9.52 M EUR
Jan 1, 2022
2.51 M EUR
Jan 1, 2023
816,900.00 EUR
Jan 1, 2024
-938,300.00 EUR
The Labiana Health Acquisitions (Net) history
YEARAcquisitions (Net)YoY
-938,300.00EUR-214.86%
816,900.00EUR-67.42%
2.51 MEUR-126.33%
-9.52 MEUR+25,986.03%
-36,500.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Acquisitions (Net) of Labiana Health is -938,300.00 EUR in 2024.

Acquisitions (Net) of Labiana Health changed from 816,900.00 EUR to -938,300.00 EUR, representing a -214.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Labiana Health since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Labiana Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Labiana Health

All Key Metrics — Labiana Health